Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Tumour Biol · ISSN (print) 1010-4283 · 11 papers in corpus
2016
doi:10.1007/s13277-015-4733-z ·PMID:26753953

After several years of research, HE4 was found to be characterized by slightly worse sensitivity but significantly higher specificity as compared with CA125. Further studies led to the diagnostic potential of both markers (CA125 and HE4) be…

2016
doi:10.1007/s13277-016-4784-9 ·PMID:26779635

An attempt was made to compare the usefulness of determining markers carcinoembryonic antigen (CEA) and tumor-associated trypsin inhibitor (TATI) in endometrial cancer patients in whom recurrence or distant metastasis was diagnosed in obser…

2015
doi:10.1007/s13277-014-2738-7 ·PMID:25326813

Human epididymis protein 4 (HE4) levels and the Risk of Ovarian Malignancy Algorithm (ROMA) have recently been shown to improve the sensitivity and specificity of epithelial ovarian cancer (EOC) diagnosis. We evaluated HE4 levels and ROMA a…

article 2014
doi:10.1007/s13277-014-1945-6 ·PMID:24771264

The aim of this study is to evaluate the diagnostic performance of human epididymis protein 4 (HE4), cancer antigen 125 (Ca125) and the risk of ovarian malignancy algorithm (ROMA) in discriminating ovarian cancer from other benign gynaecolo…

2013
doi:10.1007/s13277-013-0748-5 ·PMID:23558962

Uterine sarcomas and mixed epithelial-mesenchymal uterine tumors are a heterogeneous group of rare tumors for which there are very few diagnostic markers available. As aberrant microRNA (miRNA) expression patterns represent putative diagnos…

2012
doi:10.1007/s13277-011-0256-4 ·PMID:22105734

The objectives of this study are to establish reference limits for human epididymis protein 4, HE4, and investigate factors influencing HE4 levels in healthy subjects. HE4 was measured in 1,591 samples from the Nordic Reference Interval Pro…

article 2011
doi:10.1007/s13277-011-0204-3 ·PMID:21863264

The aim of this study is to evaluate a new tumour marker, HE4, in comparison with CA 125 and the Risk of Ovarian Malignancy Algorithm (ROMA) in healthy women and in patients with benign and malignant gynaecological diseases. CA 125 and HE4 …

review 1998
doi:10.1159/000030009 ·PMID:9591048

Glycodelins are 28 to 30-kD glycoproteins synthesized in various glands, notably those of the male and female reproductive organs. Depending on the site of origin, the same protein backbone is glycosylated in different ways, yielding glycod…

other 1994
doi:10.1159/000217896 ·PMID:7939172

Human chorionic gonadotropin (hCG) is a glycoprotein of which sugar chains are considered to show structural changes with malignancy. To study the sugar chain heterogeneity of urinary hCG in patients with gynecological disease, we employed …

other 1993
doi:10.1159/000217819 ·PMID:7684152

The aim of this study was to establish whether different subsets of ovarian neoplasms express a restricted isotype of carcinoembryonic antigen (CEA) which can be detected in solid tumors and detached cells. Sixty-one cases of mucinous, sero…

other 1985
·PMID:3915587

In addition to its presence in extracts of carcinomatous tissues from the vulva, endometrium and ovary, PLAP can also be found in tissue extracts of benign conditions of the endometrium and myometrium. We detected slightly elevated levels o…